Adaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South Africa

对移动医疗和传统依从性支持干预措施进行适应性评估,以优化南非耐药结核病和艾滋病毒新治疗方案的结果

基本信息

  • 批准号:
    10589840
  • 负责人:
  • 金额:
    $ 58.37万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-03-10 至 2027-02-28
  • 项目状态:
    未结题

项目摘要

Project Summary/Abstract Tuberculosis (TB) is the leading cause of mortality among people living with HIV, causing one in three deaths world-wide. In southern Africa, interaction between TB and HIV epidemics has led to increased transmission of drug-resistant TB (DR-TB), critically undermining both TB and HIV- related treatment targets. Bedaquiline (BDQ) is the first new TB drug in over 40 years, and the World Health Organization recommends the inclusion of BDQ in DR-TB treatment allowing for more effective, entirely oral DR-TB treatment. Despite challenges, BDQ rollout in South Africa has been highly successful in reducing TB associated-mortality and improving cure rates. Dolutegravir, an integrase strand transfer inhibitor, formulated as part of a once-daily combination antiretroviral therapy (ART), is newly available in the South African public health system. Tenofovir/lamivudine/dolutegravir (TLD) is superior to older comparator regimens, protective for discontinuation due to adverse events, and has minimal interaction with BDQ. The availability of TLD and BDQ has radically transformed the treatment paradigm for DR-TB HIV but advances in dual adherence support are needed to realize the benefits of new therapeutics for patients, and to prevent emergent resistance. Patient-centered adherence support strategies using psychosocial support and mHealth (health practices supported by mobile technologies) approaches may improve DR-TB HIV outcomes. The goal of the proposed study is to evaluate an integrated intervention to enhance adherence to BDQ and TLD. Using a Bayesian, adaptive randomized trial design, this project will efficiently evaluate the relative contribution of psychosocial support and cellular-supported mHealth adherence support, in combination and separately, to improve clinical and biological outcomes for HIV and TB. BDQ adherence measured using cellular-enabled electronic pill boxes, will allow us to determine optimal adherence thresholds associated with TB culture conversion. We will use a model-based approach to characterize socio-behavioral mechanisms of action for the different intervention arms (including potential non-response), and modifiable factors that present barriers and facilitators to adherence. We will also evaluate the effect of DR-TB HIV intersectional stigma on adherence. Qualitative methods will allow for longitudinal description of patient- centered treatment pathways. Once completed, this study will meet the expressed need of the South African health system for evidence-based DR-TB HIV adherence interventions and contribute generalizable knowledge about the relative contributions of adherence support modalities in medically complex patients.
项目总结/摘要 结核病是艾滋病毒感染者死亡的主要原因, 全世界有三人死亡在南部非洲,结核病和艾滋病毒流行之间的相互作用导致 耐药结核病(DR-TB)的传播增加,严重破坏结核病和艾滋病毒- 相关治疗目标。贝达喹啉(BDQ)是40多年来第一种新的结核病药物, 世界卫生组织建议将BDQ纳入耐药结核病治疗, 更有效的完全口服耐药结核病治疗。尽管面临挑战,BDQ在南非推出 在降低结核病相关死亡率和提高治愈率方面非常成功。 Dolutegravir,一种整合酶链转移抑制剂,作为每日一次复方制剂的一部分 抗逆转录病毒疗法(ART)是南非公共卫生系统新近提供的。 替诺福韦/拉米夫定/度鲁特韦(Tenofovir/lamivudine/dolutegravir)上级旧的比较方案, 由于不良事件而停药,与BDQ的相互作用极小。 抗结核药物和BDQ的可用性从根本上改变了耐药结核病的治疗模式 艾滋病毒,但需要在双重坚持支持方面取得进展,以实现新的 治疗患者,并防止出现耐药性。以患者为中心的依从性 使用心理社会支持和移动健康(由移动的支持的健康实践)的支持战略 技术)方法可能会改善耐药结核病艾滋病毒的结果。 这项研究的目的是评估一种综合干预措施,以提高依从性 到BDQ和BDD。使用贝叶斯,适应性随机试验设计,该项目将有效地 评估心理社会支持和手机支持的移动健康的相对贡献 联合或单独提供依从性支持,以改善临床和生物学结局 艾滋病和结核病的治疗使用蜂窝式电子药盒测量的BDQ依从性将允许 确定与结核菌培养转化相关的最佳依从性阈值。我们将 使用基于模型的方法来描述社会行为的行动机制, 不同的干预组(包括潜在的无应答),以及存在的可改变因素 阻碍和促进因素。我们还将评估耐药结核病和艾滋病毒交叉感染的影响, 坚持的耻辱。定性方法将允许对患者进行纵向描述- 中心治疗路径。 这项研究一旦完成,将满足南非卫生系统的明确需求。 支持循证耐药结核病艾滋病毒依从性干预措施,并提供可推广的知识 关于医学复杂患者中依从性支持模式的相对贡献。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Max O'Donnell其他文献

Max O'Donnell的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Max O'Donnell', 18)}}的其他基金

Rapid phenotypic detection of complex and emergent TB drug-resistance using a next-generation nanoluciferase reporter phage
使用下一代纳米荧光素酶报告噬菌体快速表型检测复杂和突发的结核病耐药性
  • 批准号:
    10662977
  • 财政年份:
    2023
  • 资助金额:
    $ 58.37万
  • 项目类别:
Adaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South Africa
对移动医疗和传统依从性支持干预措施进行适应性评估,以优化南非耐药结核病和艾滋病毒新治疗方案的结果
  • 批准号:
    10484620
  • 财政年份:
    2022
  • 资助金额:
    $ 58.37万
  • 项目类别:
Targeted next-generation sequencing to enhance detection and genomic characterization of Mycobacterium tuberculosis and high-impact bacterial pathogens among HIV-infected adults with sepsis in Uganda
靶向下一代测序可增强乌干达感染艾滋病毒的脓毒症成人中结核分枝杆菌和高影响细菌病原体的检测和基因组特征
  • 批准号:
    10116263
  • 财政年份:
    2020
  • 资助金额:
    $ 58.37万
  • 项目类别:
Targeted next-generation sequencing to enhance detection and genomic characterization of Mycobacterium tuberculosis and high-impact bacterial pathogens among HIV-infected adults with sepsis in Uganda
靶向下一代测序可增强乌干达感染艾滋病毒的脓毒症成人中结核分枝杆菌和高影响细菌病原体的检测和基因组特征
  • 批准号:
    9927189
  • 财政年份:
    2020
  • 资助金额:
    $ 58.37万
  • 项目类别:
Promoting Engagement in the Drug Resistant TB/HIV Care Continuum in South Africa
促进南非耐药结核病/艾滋病毒护理连续体的参与
  • 批准号:
    9254436
  • 财政年份:
    2016
  • 资助金额:
    $ 58.37万
  • 项目类别:
Promoting Engagement in the Drug Resistant TB/HIV Care Continuum in South Africa
促进南非耐药结核病/艾滋病毒护理连续体的参与
  • 批准号:
    9894715
  • 财政年份:
    2016
  • 资助金额:
    $ 58.37万
  • 项目类别:
Promoting Engagement in the Drug Resistant TB/HIV Care Continuum in South Africa
促进南非耐药结核病/艾滋病毒护理连续体的参与
  • 批准号:
    9117193
  • 财政年份:
    2016
  • 资助金额:
    $ 58.37万
  • 项目类别:
Biomarker for XDR-TB Treatment Response and Drug Resistance in HIV Endemic Area
HIV 流行地区广泛耐药结核病治疗反应和耐药性的生物标志物
  • 批准号:
    8410973
  • 财政年份:
    2012
  • 资助金额:
    $ 58.37万
  • 项目类别:
Biomarker for XDR-TB Treatment Response and Drug Resistance in HIV Endemic Area
HIV 流行地区广泛耐药结核病治疗反应和耐药性的生物标志物
  • 批准号:
    8508846
  • 财政年份:
    2012
  • 资助金额:
    $ 58.37万
  • 项目类别:
Biomarker for XDR-TB Treatment Response and Drug Resistance in HIV Endemic Area
HIV 流行地区广泛耐药结核病治疗反应和耐药性的生物标志物
  • 批准号:
    9088299
  • 财政年份:
    2012
  • 资助金额:
    $ 58.37万
  • 项目类别:

相似海外基金

Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
  • 批准号:
    10591918
  • 财政年份:
    2023
  • 资助金额:
    $ 58.37万
  • 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
  • 批准号:
    23K15383
  • 财政年份:
    2023
  • 资助金额:
    $ 58.37万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
  • 批准号:
    23H03556
  • 财政年份:
    2023
  • 资助金额:
    $ 58.37万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
  • 批准号:
    23K17212
  • 财政年份:
    2023
  • 资助金额:
    $ 58.37万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
  • 批准号:
    22H03519
  • 财政年份:
    2022
  • 资助金额:
    $ 58.37万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
  • 批准号:
    563657-2021
  • 财政年份:
    2022
  • 资助金额:
    $ 58.37万
  • 项目类别:
    Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10521849
  • 财政年份:
    2022
  • 资助金额:
    $ 58.37万
  • 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10671022
  • 财政年份:
    2022
  • 资助金额:
    $ 58.37万
  • 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
  • 批准号:
    10670918
  • 财政年份:
    2022
  • 资助金额:
    $ 58.37万
  • 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
  • 批准号:
    RGPIN-2018-04753
  • 财政年份:
    2022
  • 资助金额:
    $ 58.37万
  • 项目类别:
    Discovery Grants Program - Individual
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了